27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ:VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat recurrent glioblastoma (GBM) patients with first tumor recurrence.
- The company also announced the most recent tumor response and overall survival (OS) data from the Phase 1/2a study at the American Society of Clinical Oncology Annual Meeting.
- Study arm 1: VBI-1901 + granulocyte-macrophage colony-stimulating factor (GM-CSF)
- 6-month and 12-month OS : 80% (n=8/10) and 60% (n=6/10), respectively.
- Two partial responses and two stable disease observations – 40% disease control rate.
- Study arm 2: VBI-1901 + GlaxoSmithKline plc's (NYSE: GSK) AS01B adjuvant system.
- 6-month OS : 89% (n=8/9) – 12-month OS not yet reached. 5 stable disease observations – 50% disease control rate.
- Historical control data have demonstrated overall survival to be ~60% at 6-months and ~30% at 12-months after treatment with a monotherapy.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: VBIV shares are up 4.1% at $3.61 during the market session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!